Scientific Advisory Board (SAB)
The ProMIS SAB brings together a multidisciplinary group of specialists in Alzheimer’s and neurodegenerative diseases along with experts in neurotoxic, propagating misfolded proteins (toxic oligomers). The current members of the Company’s SAB are:
- Neil R. Cashman, MD., is Chief Science Officer at ProMIS Neurosciences and Professor of Medicine at the University of British Columbia, where he holds the Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases and serves as the Director of the UBC ALS Centre. Dr. Cashman is recognized as a pioneer in the field of prions and their role in the development of neurodegenerative diseases, in particular ALS and AD. Neil Cashman is co-chair of the SAB.
- Sharon Cohen, MD., is Medical Director and Principal Investigator of Toronto Memory Program, an independent medical facility for dementia care and research. Her memory clinic and dementia clinical trials program are the largest and most active in Canada and have contributed substantially to patient care and to global clinical trial cohorts. Dr. Cohen holds an FRCPC in neurology from the Royal College of Physicians of Canada and a fellowship in Behavioural Neurology from the University of Toronto.
- Hans Frykman MD, PhD, is the CEO and medical director of BC Neuroimmunology Lab and Neurocode Labs. BC Neuroimmunology lab has a 35-year history of delivering highly specific clinical neuroimmunology testing to the North American marketplace. The lab is a technology leader and is academically collaborating with several leading centers in Europe and USA. Neurocode labs is Canada’s first and only clinical whole exome sequencing facility. It has a particular focus in seizure disorder, cardiac sequencing and sequencing of the neonate. Dr. Frykman is a clinical assistant professor of medicine at University of BC. Dr. Frykman received his postgraduate medical training at Karolinska University Hospital, Mayo Clinic, University of Minnesota, Memorial Sloan Kettering Cancer Center, and University of British Columbia. Dr Frykman received his medical degree from Karolinska Institute in Stockholm, PhD in Bio-organic chemistry from Royal Institute of Technology in Stockholm and MSc in Chemical Engineering from Chalmers University in Gothenburg.
- Todd E. Golde, MD., PhD., is Director of the Center for Translational Research in Neurodegenerative Disease at the University of Florida where he directs a robust program of scientific discovery aimed at translating basic discoveries in neurodegenerative disease into diagnostics and treatments for patients. Dr. Golde is co-chair of the SAB.
- William C. Mobley, MD., PhD., is Associate Dean for Neurosciences Initiatives, Distinguished Professor of Neurosciences, and Florence Riford Chair for Alzheimer Disease at the University of California, San Diego where he also serves as Executive Director of the university’s Down Syndrome Center for Research and Treatment. Dr. Mobley’s research focuses on the neurobiology of neuronal dysfunction in developmental and age-related disorders of the nervous system. He has conducted pioneering work on the neurobiology of Alzheimer’s disease and Down syndrome.
- José Luis Molinuevo, MD, PhD, is the Scientific Director of the Alzheimer Prevention Program at the BarcelonaBeta Brain Research Center (BBRC) in Barcelona, Spain, which focuses on Alzheimer’s disease prevention from a clinical, cognitive, genetic, and biomarker perspective. He is an associate professor at the University Pompeu Fabra, member of several professional societies governing neurodegenerative diseases, principal investigator of multiple clinical trials and research studies on AD and author of more than 330 international scientific papers, several books and over 20 book chapters on neurodegenerative diseases. He received his MD from the University of Valencia and his PhD in neurology from the University of Barcelona.
- C. Warren Olanow, MD., C. Warren Olanow has authored more than 300 publications primarily related to Parkinson’s disease and neurodegeneration. He is the previous Henry P. and Georgette Goldschmidt Professor and Chairman of the Department of Neurology at the Mount Sinai School of Medicine in New York City, and is presently Professor Emeritus in the Department of Neurology and in the Department of Neuroscience. He also serves as Chief Executive Officer of CLINTREX, a pharmaceutical advisory firm that has designed numerous clinical trials in neurodegenerative disease for the pharmaceutical industry.
- Andre Strydom, MD, PhD, is a professor in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London, and Honorary Consultant psychiatrist, South London and the Maudsley NHS Trust. His current projects and collaborations include the LonDownS consortium, funded by the Wellcome Trust/ MRC, to study the neurobiology of Alzheimer’s Disease in Down syndrome to understand the underlying factors that may influence variation in age of onset of symptoms. His research in Down syndrome includes investigation of biomarkers of cognitive decline including those related to excess amyloid production, oxidative stress, and neurodegeneration. His group also conducts neuroimaging studies using high-density EEG, MRI and fNIRS. He has been an investigator on clinical trials of new drug treatment options in Down syndrome, fragile X syndrome and autism.
- Rudolph E. Tanzi, PhD., is a neuroscientist and geneticist with scientific expertise in Alzheimer’s disease and brain health. He serves as Vice-Chair of Neurology, Director of the Genetics and Aging Research Unit, and as a Director of the Henry and Allison McCance Center for Brain Health at Massachusetts General Hospital. He is also the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School.
- Lary C. Walker, PhD., is Associate Professor of Neurology and Research Professor at Emory University Yerkes National Primate Research Center. Lary Walker’s research has been directed toward understanding the mechanisms by which the Alzheimer-associated proteins Amyloid beta and tau form pathogenic assemblies in vivo and how these agents spread in the brain.
Business Advisory Board
The ProMIS Business Advisory Board brings together recognized leaders in the fields of biotech business management, diagnostic product development and monoclonal antibody design and manufacture. The current members of the business advisory board are:
- Nigel Burns, PhD., has over 20 years’ experience in the biotech sector, in particular in the field of monoclonal antibodies for the treatment of chronic disease. Nigel has held a series of industry leadership roles including Senior Vice President of Cambridge Antibody Technology, and most recently, CEO and Founder of SweetSpot Therapeutics Ltd. Nigel was entrepreneur-in-residence for Imperial Innovations and has served on multiple national and international scientific and industry advisory boards and committees.
- Michael Higgins, MBA, is currently an entrepreneur-in-residence at Polaris Partners. Previously at Genzyme, Mr. Higgins held a variety of leadership roles, including Vice President of Corporate Finance and Vice President of Business Development, and was involved with multiple business units, including Cell Therapy, Gene Therapy and Orphan Diseases.
- Timothy G. Rothwell, JD, currently serves as Chairman of Emisphere Technologies Inc. (OTC:EMIS), and Chairman of Speracura LLC, a healthcare consulting company. Mr. Rothwell is the former U.S Chairman for Sanofi-Aventis (Sanofi) after serving as its president and CEO for several years. Earlier in his career, Mr. Rothwell served as CEO of Sandoz Pharmaceuticals and president of Rhone-Poulenc Rorer Pharmaceuticals. Tim has held board positions with several pharmaceutical companies and served as a trustee at the Children’s Health Fund, on the Institute of Medicine’s Evidence-Based Medicine roundtable and as Chairman of the Pheo Para Alliance, a non-profit organization serving patients with pheochromocytoma and paraganglioma.